Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant tebentafusp in metastatic uveal melanoma
2023-509076-42-00Phase 2Authorised
- Sponsor
- Gem
- Start
- Jul 2025
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of tebentafusp in intraocular melanoma, sponsored by Gem. Primary endpoint: Pathological complete response rate. Planned start Jul 2025; status: authorised.
02
Drugs
tebentafusp
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on 2023-509076-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509076-42-00.